[1] Hautekeete ML,Degott C,Benhamou JP. Microvesicular steatosis of the liver. Acta Clin Belg,1990,45:311-326.
[2] Genève J,Hayat-Bonan B,Labbe G,et al. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther,1987,242:1133-1137.
[3] Caldwell SH,Hespenheide EE,von Borstel RW. Myositis, microvesicular hepatitis,and progression to cirrhosis from troglitazone added to simvastatin.Dig Dis Sci,2001,46:376-378.
[4] Delzenne NM,Hernaux NA,Taper HS. A new model of acute liver steatosis induced in rats by fasting followed by refeeding a high carbohydrate-fat free diet:Biochemical and morphological analysis. J Hepatol,1997,26:880-885.
[5] Labbe G,Pessayre D,Fromenty B. Drug-induced liver injury through mitochondrial dysfunction:mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol,2008,22:335-353.
[6] Pessayre D,Mansouri A,Berson A,et al. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol,2010,196:311-365.
[7] Baldwin GS,Murphy VJ,Yang Z,et al. Binding of nonsteroidal antiinflammatory drugs to the α-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther,1998,286:1110-1114.
[8] Larosche I,Lettéron P,Fromenty B,et al. Tamoxifen inhibits topoisomerases,depletes mitochondrial DNA,and triggers steatosis in mouse liver. J Pharmacol Exp Ther,2007,321:526-535.
[9] Silva MF,Ruiter JP,Ijlst L,et al. Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites. Anal Biochem,2001,290:60-67.
[10] Labbe G,Pessayre D,Fromenty B. Drug-induced liver injury through mitochondrial dysfunction:mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol,2008,22:335-353.
[11] Igoudjil A,Begriche K,Pessayre D,et al. Mitochondrial, metabolic and genotoxic effects of antiretroviral nucleoside reverse-transcriptase inhibitors. Anti-Infect Agents Med Chem,2006,5:273-292.
[12] Schadinger SE,Bucher NL,Schreiber BM,et al. PPARγ2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab,2005,288:E1195-E1205.
[13] Macfarlane DP,Forbes S,Walker BR. Glucocorticoids and fatty acid metabolism in humans:fuelling fat redistribution in the metabolic syndrome. J Endocrinol,2008,197:189-204.
[14] Lettéron P,Sutton A,Mansouri A,et al. Inhibition of microsomal triglyceride transfer protein:another mechanism for drug-induced steatosis in mice. Hepatology,2003,38:133-140.
[15] Verrotti A,Di Marco G,la Torre R,et al. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr,2009,168:1391-1394.
[16] Letteron P,Brahimi-Bourouina N,Robin MA,et al. Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. Am J Physiol,1997,272:G1141-1150.
[17] Rigas B. The evolving spectrum of amiodarone hepatotoxicity. Hepatology,1989,10:116-117.
[18] Saphner T,Triest-Robertson S,Li H,et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer,2009,115:3189-3195. |
